Skip to main content
. 2019 May 10;155(10):1142–1152. doi: 10.1001/jamadermatol.2019.1121

Table 1. Baseline Characteristics by Medication Cohort for Optum Clinformatics Data Mart and Truven MarketScan.

Variable No. (%)
Reference Group: MTX Users (Compared With Adalimumab)a Adalimumab Users Acitretin Users Apremilast Users Etanercept Users Infliximab Users Ustekinumab Users Total Across Medications
Optum
Patients, y, No. 8470 7181 2726 1623 7102 408 4085 31 595
Age, y
Mean (SD) 53.69 (15.48) 46.10 (12.97) 52.31 (13.89) 51.37 (13.77) 45.45 (12.99) 50.20 (14.59) 46.50 (12.84) NAb
Categories
18-54 4387 (51.8) 5255 (73.2) 1506 (55.2) 944 (58.2) 5332 (75.1) 253 (62.0) 2974 (72.8) 20 651 (65.4)
55-64 1892 (22.3) 1389 (19.3) 759 (27.8) 417 (25.7) 1304 (18.4) 85 (20.8) 815 (20.0) 6661 (22.1)
65-74 1484 (17.5) 449 (6.3) 324 (11.9) 201 (12.4) 372 (5.2) 49 (12.0) 236 (5.8) 3115 (9.9)
≥75 707 (8.3) 88 (1.2) 137 (5.0) 61 (3.8) 94 (1.3) 21 (5.1) 60 (1.5) 1168 (3.7)
Sex
Male 4043 (47.7) 4061 (56.6) 1582 (58.0) 820 (50.5) 3903 (55.0) 202 (49.5) 2302 (56.4) 16 913 (53.5)
Female 4426 (52.3) 3120 (43.4) 1144 (42.0) 803 (49.5) 3199 (45.0) 206 (50.5) 1781 (43.6) 14 679 (46.5)
Unknown 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.0) 3 (0.0)
Obese 526 (6.2) 372 (5.2) 137 (5.0) 87 (5.4) 336 (4.7) 27 (6.6) 251 (6.1) 1736 (5.5)
Smokers 477 (5.6) 326 (4.5) 148 (5.4) 57 (3.5) 332 (4.7) 24 (5.9) 184 (4.5) 1548 (4.9)
Depression 191 (2.3) 178 (2.5) 45 (1.7) 27 (1.7) 176 (2.5) 13 (3.2) 76 (1.9) 706 (2.2)
Combined comorbidity score, mean (SD) 0.14 (1.03) 0.07 (0.79) 0.14 (1.08) 0.14 (0.85) 0.07 (0.81) 0.23 (1.13) 0.08 (0.78) NAb
Region
Northeast 771 (9.1) 602 (8.4) 305 (11.2) 209 (12.9) 662 (9.3) 34 (8.3) 423 (10.4) 3006 (9.5)
Midwest 2140 (25.3) 1771 (24.7) 582 (21.3) 380 (23.4) 1659 (23.4) 137 (33.6) 975 (23.9) 7644 (24.2)
South 3719 (43.9) 3726 (51.9) 1388 (50.9) 706 (43.5) 3708 (52.2) 195 (47.8) 2027 (49.6) 15 469 (49.0)
West 1813 (21.4) 1075 (15.0) 447 (16.4) 326 (20.1) 1064 (15.0) 42 (10.3) 656 (16.1) 5423 (17.2)
Other 27 (0.3) 7 (0.1) 4 (0.1) 2 (0.1) 9 (0.1) 0 (0.0) 4 (0.1) 53 (0.17)
Commercial/Medicare
Commercial 6304 (74.4) 6740 (93.9) 2371 (87.0) 1389 (85.6) 6720 (94.6) 351 (86.0) 3807 (93.2) 27 682 (87.6)
Medicare 2166 (25.6) 441 (6.1) 355 (13.0) 234 (14.4) 382 (5.4) 57 (14.0) 278 (6.8) 3913 (12.4)
Nursing home resident 33 (0.4) 4 (0.1) 8 (0.3) 4 (0.2) 4 (0.1) 3 (0.7) 6 (0.1) 62 (0.2)
≥1 Outpatient office visit 8155 (96.3) 7065 (98.4) 2658 (97.5) 1605 (98.9) 6961 (98.0) 402 (98.5) 4026 (98.6) 30 872 (97.7)
≥1 Emergency department visit 806 (9.5) 551 (7.7) 236 (8.7) 131 (8.1) 482 (6.8) 45 (11.0) 314 (7.7) 2565 (8.1)
≥1 Inpatient hospitalization 416 (4.9) 241 (3.4) 125 (4.6) 63 (3.9) 315 (4.4) 32 (7.8) 115 (2.8) 1307 (4.1)
≥1 Laboratory test 6473 (76.4) 5794 (80.7) 2045 (75.0) 1142 (70.4) 5457 (76.8) 364 (89.2) 3244 (79.4) 24 519 (77.6)
Truven MarketScan
Patients, No. 20 609 17 912 7456 4476 16 791 1027 7841 76 112
Age, y
Mean (SD) 50.62 (13.82) 46.20 (12.89) 53.00 (12.99) 50.52 (12.84) 46.65 (13.27) 48.18 (12.47) 46.89 (12.86) NAb
Categories
18-54 12 100 (58.7) 12 848 (71.7) 3822 (51.3) 2631 (58.8) 11 790 (70.2) 691 (67.3) 5502 (70.2) 49 384 (64.9)
55-64 5819 (28.2) 4064 (22.7) 2505 (33.6) 1373 (30.7) 3800 (22.6) 252 (24.5) 1821 (23.2) 19 634 (25.8)
65-74 1791 (8.7) 767 (4.3) 773 (10.4) 359 (8.0) 894 (5.3) 62 (6.0) 404 (5.2) 5050 (6.6)
≥75 899 (4.4) 233 (1.3) 356 (4.8) 113 (2.5) 307 (1.8) 22 (2.1) 114 (1.5) 2044 (2.7)
Sex
Male 9604 (46.6) 9903 (55.3) 4222 (56.6) 2176 (48.6) 9101 (54.2) 474 (46.2) 4303 (54.9) 39 783 (52.3)
Female 11 005 (53.4) 8009 (44.7) 3234 (43.4) 2300 (51.4) 7690 (45.8) 553 (53.8) 3538 (45.1) 36 329 (47.7)
Obese 843 (4.1) 746 (4.2) 256 (3.4) 245 (5.5) 607 (3.6) 59 (5.7) 379 (4.8) 3135 (4.1)
Smokers 812 (3.9) 711 (4.0) 284 (3.8) 169 (3.8) 536 (3.2) 50 (4.9) 357 (4.6) 2919 (3.8)
Depression 987 (4.8) 879 (4.9) 319 (4.3) 141 (3.2) 825 (4.9) 65 (6.3) 364 (4.6) 3580 (4.7)
Combined comorbidity score, mean (SD) 0.08 (0.82) 0.05 (0.72) 0.08 (0.91) 0.08 (0.81) 0.06 (0.72) 0.18 (1.04) 0.05 (0.77) NAb
Region
Northeast 3088 (15.0) 2588 (14.4) 1323 (17.7) 994 (22.2) 2428 (14.5) 158 (15.4) 1494 (19.1) 12 073 (15.9)
North Central 4940 (24.0) 4266 (23.8) 1611 (21.6) 986 (22.0) 4210 (25.1) 244 (23.8) 1595 (20.3) 17 852 (23.5)
South 8478 (41.1) 8210 (45.8) 3022 (40.5) 1928 (43.1) 7251 (43.2) 531 (51.7) 3560 (45.4) 32 980 (43.3)
West 3777 (18.3) 2547 (14.2) 1420 (19.0) 554 (12.4) 2576 (15.3) 87 (8.5) 1016 (13.0) 11 977 (15.7)
Unknown 326 (1.6) 301 (1.7) 80 (1.1) 14 (0.3) 326 (1.9) 7 (0.7) 176 (2.2) 1230 (1.6)
Commercial/Medicare
Commercial 17 872 (86.7) 16 896 (94.3) 6297 (84.5) 3995 (89.3) 15 563 (92.7) 935 (91.0) 7299 (93.1) 68 857 (90.5)
Medicare 2737 (13.3) 1016 (5.7) 1159 (15.5) 481 (10.7) 1228 (7.3) 92 (9.0) 542 (6.9) 7255 (9.5)
Nursing home resident 26 (0.1) 9 (0.1) 9 (0.1) 5 (0.1) 7 (0.0) 2 (0.2) 9 (0.1) 67 (0.1)
≥1 Outpatient office visit 19 848 (96.3) 17 644 (98.5) 7261 (97.4) 4427 (98.9) 16 417 (97.8) 1018 (99.1) 7735 (98.6) 74 350 (97.7)
≥1 Emergency department visit 2256 (10.9) 1721 (9.6) 717 (9.6) 473 (10.6) 1676 (10.0) 148 (14.4) 754 (9.6) 7745 (10.2)
≥1 Inpatient hospitalization 886 (4.3) 636 (3.6) 334 (4.5) 192 (4.3) 706 (4.2) 69 (6.7) 259 (3.3) 3082 (4.0)
≥1 Laboratory test 15 896 (77.1) 15 016 (83.8) 5465 (73.3) 3264 (72.9) 13 033 (77.6) 907 (88.3) 6332 (80.8) 59 913 (78.7)

Abbreviations: MTX, methotrexate; NA, not available.

a

Results presented for methotrexate users were obtained from the adalimumab comparative analysis.

b

Groups were not completely mutually exclusive, and thus a pooled standard deviation could not be calculated for the mean.